Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYRIOS SARS-CoV-2 vaccine immune response study in relapsing multiple sclerosis patients treated with ofatumumab
2021-000307-20Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ofatumumab and RH109 in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Started Feb 2021; status: completed.
02
Drugs
ofatumumabRH109
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-000307-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000307-20.